Menatetrenone ( DrugBank: Menatetrenone )
1 disease
| ID | Disease name (Link within this page) | Number of trials |
|---|---|---|
| 66 | IgA nephropathy | 1 |
66. IgA nephropathy
Clinical trials : 275 / Drugs : 258 - (DrugBank : 82) / Drug target genes : 36 - Drug target pathways : 140
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | JPRN-UMIN000002474 | 2007/01/01 | 01/10/2009 | Preventive effect of vit K, vit D and, risedronate on 3-dimensional trabecular microstructure in patients with IgA nephropathy on glucocorticoid treatment | Preventive effect of vit K, vit D and, risedronate on 3-dimensional trabecular microstructure in patients with IgA nephropathy on glucocorticoid treatment - The Preventive Risedronate Intervention for those Undergoing Steroid therapy with IgA nephropathy (PRIUS-IgA Study ) | Glucocorticoid induced osteoporosis in patients with IgA nephropathy | Menatetrenone 45mg/day for 6 months Calcitriol 0.5 microgram/day for 6 months Risedronate 17.5mg/week for 6 months | Osaka University HospitalDepartment of nephrology | NULL | Complete: follow-up complete | 18years-old | Not applicable | Male and Female | 30 | Not applicable | Japan |